API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Hiyasta (HBI-8000) is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer. it targets class I histone deacetylases and suppresses expression of viral oncogene HTLV-I bZIP factor, NF-kB and the inflammasome in ATLL cells.
Lead Product(s): Tucidinostat
Therapeutic Area: Oncology Product Name: Hiyasta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
HUYABIO will complete the development of HBI-8000 for PTCL and ATL in Japan for commercialization by Meiji who will hold exclusive sales and marketing rights.
Lead Product(s): Tucidinostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Meiji Seika Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 08, 2020